Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Safety Study of Flu Vaccine in Immunodepression Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* informed consent signed~* Age between 18 to 64~* Patient suffering from chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis, or indeterminate colitis)~* For patients receiving at least one immunosuppressive or anti-TNF therapy: treatment introduced for at least 3 months~* Patient willing to participate in the study throughout its duration and acceptance procedures related to the study (blood samples, self questionnaires, nasal swab and telephone follow-up)~Exclusion criteria :~* Patient treated by corticosteroid alone without immunosuppressive or anti-TNF~* For women, being pregnant or positive pregnancy test~* Known allergy to any component of the study vaccine or a history of hypersensitivity reaction to influenza vaccination~* Fever (at least 37.5°C measured orally) or acute infection in the week prior to vaccination~* Received influenza vaccination in the 6 months preceding enrollment~* Known history of progressive neuropathy or Guillain-Barre~* Known infection with HIV and/or HBV (Ag-HBs positive) and/or HCV~* Other causes of severe immune deficiency~* Cellular therapy, immunoglobulin infusions, of blood products or monoclonal antibodies (except anti-TNF) in the 3 months prior to vaccination~* Patient deprived of freedom by an administrative or court order~* Patient non affiliated to a health social security system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
- 3 (Type: EXPERIMENTAL): patients with IBD receiving immunosuppressants including TNF blockers (n=100)
- 1 (Type: EXPERIMENTAL): patients with IBD not receiving immunosuppressant (n=100)
- 4 (Type: ACTIVE_COMPARATOR): patients with IBD receiving immunosuppressants including TNF blockers (n=20)

Based on this trial design, predict the completion outcome and termination type (if applicable).